SCHEMBL5624294

SCHEMBL5624294

Nc1cc(-c2cccnc2)ccc1S(N)(=O)=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.59
CA9 Q16790 2/20 0.59
CA12 O43570 1/20 0.59
CA1 P00915 1/20 0.59
MKNK1 Q9BUB5 6/20 0.51
MKNK2 Q9HBH9 6/20 0.51
MEN1 O00255 1/20 0.51
PSIP1 O75475 1/20 0.51
AXL P30530 1/20 0.51
AURKA O14965 1/20 0.50
TTK P33981 1/20 0.50
AURKB Q96GD4 1/20 0.50
INCENP Q9NQS7 1/20 0.50
HTR6 P50406 1/20 0.48
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2A6 P11509 1/20 0.47
ERN1 O75460 2/20 0.47
CYP11B1 P15538 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10040106 0.82 HTR6 (0.67) CA2CA9CA12CA1MKNK1
SCHEMBL29808069 0.80 CA2 (0.58) CA2CA9CA12CA1MKNK1
SCHEMBL8695072 0.79 CA2 (0.56) CA2CA9CA12CA1MKNK1
SCHEMBL77876 0.78 MKNK1 (0.63) MKNK1MKNK2MEN1PSIP1AXL
SCHEMBL30516501 0.78 MKNK1 (0.63) MKNK1MKNK2MEN1PSIP1AXL
SCHEMBL4703894 0.77 MEN1 (0.61) CA2CA9CA12CA1MKNK1
SCHEMBL14075569 0.76 CA9 (0.70) CA2CA9CA12CA1MKNK1
SCHEMBL28835718 0.76 CA2 (0.46) CA2CA9CA12CA1CYP3A4
SCHEMBL22497670 0.75 MKNK1 (0.65) MKNK1MKNK2MEN1PSIP1AXL
SCHEMBL11371958 0.73 MKNK1 (0.62) CA2CA9CA12CA1MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7235548-B2 Compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S (DK) 2007-06-26 US disclosed
US-6943159-B1 Compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S (DK) 2005-09-13 US disclosed
US-20040043987-A1 Novel compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S. 2004-03-04 US disclosed
CN-1293665-A New compounds and their use as positive AMPA receptor modulators NEUROSEARCH AS (DK) 2001-05-02 CN disclosed
EP-1071426-A2 NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 2001-01-31 EP disclosed
WO-1999042456-A2 NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 1999-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043987-A1 Novel compounds and their use as positive AMPA receptor modulators GRIK4, GRIA4, GRM2 CA2 365/4885CA9 3703/4885CA12 1624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.